Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C

article published in 2018

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2147/AHMT.S147896
P932PMC publication ID6071628
P698PubMed publication ID30104913

P2093author name stringAijaz Ahmed
Aparna Goel
Christine Hong Ting Yang
P2860cites workDurability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin.Q50553046
Hepatitis C virus infection in children and adolescents.Q54277218
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapyQ59360252
Chronic Hepatitis C Infection in ChildrenQ87924400
EASL Recommendations on Treatment of Hepatitis C 2016Q88412279
Daclatasvir: potential role in hepatitis CQ27012741
Burden of pediatric hepatitis CQ27025476
Small Interfering RNA Targeted to Hepatitis C Virus 5' Nontranslated Region Exerts Potent Antiviral EffectQ27478036
Impact of Hepatitis C Virus Infection on Children and Their Caregivers: Quality of Life, Cognitive, and Emotional OutcomesQ27487975
Diagnosis, management, and treatment of hepatitis C: an updateQ29619682
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002Q29619974
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionQ29620318
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionQ29620620
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health studyQ33435950
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052Q34185949
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyQ36032750
Hepatitis B and C viruses in infants and young childrenQ36279382
Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymeraseQ36513118
Approaches to hepatitis C treatment and cure using NS5A inhibitorsQ37630422
Pediatric hepatitis C infection: to treat or not to treat...what's the best for the child?Q37947635
NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescentsQ38001268
Hepatitis C virus proteins: from structure to functionQ38086751
Is genotype 3 of the hepatitis C virus the new villain?Q38155123
New treatments for chronic hepatitis C: an overview for paediatriciansQ38282842
Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort studyQ38445289
Hepatitis C in children in times of changeQ38551405
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infectionQ39058953
Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapyQ39415756
Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypesQ39421935
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic ResponseQ39449507
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort studyQ39481949
Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States and Kentucky, 2011-2014.Q39576771
Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.Q39610676
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.Q39690146
Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patientsQ39821108
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.Q39958110
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 studyQ40069100
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.Q40129813
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infectionQ40186025
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label StudyQ40189279
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 InfectionQ40352957
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infectionQ40402518
Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patientsQ40433082
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infectionQ40634052
Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus InfectionQ40700593
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsQ40950331
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infectionQ41059944
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialQ41343312
Health-Related Quality of Life in Adolescent Patients with Hepatitis C Genotype 1 Treated with Sofosbuvir and LedipasvirQ41928547
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.Q43039677
Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in childrenQ45325089
The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year periodQ45417690
Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced PatientsQ46644977
Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, with Chronic Hepatitis C Infection.Q46648340
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.Q47547989
The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.Q47551548
Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition.Q47559718
Glecaprevir + pibrentasvir for treatment of hepatitis C.Q49714606
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.Q50267668
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectteenagerQ1492760
P304page(s)103-110
P577publication date2018-01-01
P1433published inAdolescent Health, Medicine and TherapeuticsQ15816528
P1476titleClinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
P478volume9

Reverse relations

Q91796536Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4cites workP2860

Search more.